Urinary Bladder Neoplasm

Oncology·MeSH: Urinary Bladder Neoplasms

Prevalence

61.0 / 100K

Incidence

18.0 / 100K/yr

12 drugs in development·7 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
cetrelimab	GH Research PLC (GHRS)
Cetrelimab	CG Oncology, Inc. (CGON)
Intismeran autogene	Merck & Co., Inc. (MRK)
tar-200	GH Research PLC (GHRS)
TAR-200	CG Oncology, Inc. (CGON)
TAR-200	Merus N.V. (MRUS)
Vinblastine	ASTRAZENECA PLC (AZN)

Phase 2(3)

Drug	Company
BCG	Merck & Co., Inc. (MRK)
Cetrelimab	Merus N.V. (MRUS)
TAR-200	Janux Therapeutics, Inc. (JANX)

Phase 1(2)

Drug	Company
enfortumab vedotin	ELI LILLY & Co (LLY)
loxo-435	ELI LILLY & Co (LLY)

Compare drugs

cetrelimab vs Intismeran autogene cetrelimab vs tar-200 cetrelimab vs Vinblastine

Frequently asked questions

How many drugs are in development for Urinary Bladder Neoplasm?

BioSniper tracks 12 drugs in development for Urinary Bladder Neoplasm across 7 companies.

How many clinical trials target Urinary Bladder Neoplasm?

There are 2 clinical trials targeting Urinary Bladder Neoplasm tracked by BioSniper.

What is the prevalence of Urinary Bladder Neoplasm?

The estimated prevalence of Urinary Bladder Neoplasm is approximately 61.0 per 100,000 population.

Deep-dive into Urinary Bladder Neoplasm

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Urinary Bladder Neoplasm — Drugs in Development & Clinical Trials | BioSniper